Human Umbilical Cord-Mesenchymal Stem Cells: A Promising Strategy for Corneal Epithelial Regeneration

Azmi, Siti Maisura; Salih, Mohamed Ahmed; Abdelrazeg, Samar; Roslan, Fatin Fazrina; Mohamed, Rafeezul; Tan, Jun; Shaharuddin, Bakiah

doi:10.2217/rme-2019-0103

Cited by 8 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Azmi et al 88 cocultured human UC-MSCs with corneal epithelial cells and found that the MSCs promoted epithelial cell growth and function by downregulating the expression of HLA class I and diphenylamine IFN-γ stimulated human telomerase perpetuators. Park et al 71 found less ocular damage and decreased cell apoptosis in mice intravenously injected with UC-MSCs.…”

Section: Application Of Mscs In Dry Eye Treatmentmentioning

confidence: 99%

Mesenchymal Stromal Cell–Based Therapy for Dry Eye: Current Status and Future Perspectives

2022

View full text Add to dashboard Cite

Dry eye is one of the most common chronic diseases in ophthalmology. It affects quality of life and has become a public health problem that cannot be ignored. The current treatment methods mainly include artificial tear replacement therapy, anti-inflammatory therapy, and local immunosuppressive therapy. These treatments are mainly limited to improvement of ocular surface discomfort and other symptoms. In recent years, regenerative medicine has developed rapidly, and ophthalmologists are working on new methods to treat dry eye. Mesenchymal stromal cells (MSCs) have anti-inflammatory, tissue repair, and immune regulatory effects, and have become a promising tool for the treatment of dry eye. These effects can also be produced by MSC-derived exosomes (MSC-Exos). As a cell-free therapy, MSC-Exos are hypoimmunogenic, serve more stable entities, and compared with MSCs, reduce the safety risks associated with the injection of live cells. This article reviews current knowledge about MSCs and MSC-Exos, and highlights the latest progress and future prospects of MSC-based therapy in dry eye treatment.

show abstract

Section: Application Of Mscs In Dry Eye Treatmentmentioning

confidence: 99%

Mesenchymal Stromal Cell–Based Therapy for Dry Eye: Current Status and Future Perspectives

2022

View full text Add to dashboard Cite

show abstract

“…DP-MSC menunjukkan karakteristik penanda dan potensi diferensiasi yang serupa dengan MSCs yang disebutkan di atas, dibandingkan dengan UCB-MSC yang menunjukkan tingkat proliferasi yang lebih tinggi, tingkat imunomodulasi yang lebih kuat, dan tingkat penuaan yang lebih rendah [44]. Meskipun penelitian terbatas menerapkan sel-sel ini pada kornea , sebuah studi ex vivo telah menunjukkan kapasitas DP-MSCs untuk meningkatkan perbaikan dan regenerasi epitel kornea manusia, DP-MSCs yang belum matang telah menunjukkan kemanjuran in vivo untuk defisiensi sel induk limbal, menyebabkan penurunan opasitas kornea dan neovaskularisasi [53] selain secara langsung dan tidak langsung menginduksi penyembuhan luka epitel kornea in vitro menyoroti potensi mereka sebagai agen terapeutik [54,55].…”

Section: Msc Dari Sumber Lainunclassified

Sel Induk Mesenchymal Secretome untuk Gangguan Permukaan Okular

2022

View full text Add to dashboard Cite

Gangguan permukaan okular adalah sekelompok penyakit heterogen yang sangat umum dengan berbagai etiologi dan gejala serta merupakan faktor risiko dengan komplikasi serius pada mata. Obat-obatan saat ini termasuk obat tetes mata yang dijual bebas tidak mengobati gangguan permukaan okular atau telah dikaitkan dengan berbagai efek samping yang mengarah pada pengobatan alternatif menggunakan terapi sel induk. Sel induk mesenchymal (MSC) adalah sel induk multipoten yang berpartisipasi dalam perbaikan jaringan dan memiliki potensi imunomodulator yang cukup besar untuk mengatasi gangguan permukaan okular. MSC mensekresi secretome dengan aktivitas autokrin dan parakrin yang bekerja menghambatan fibrosis dan apoptosis, penekanan sistem kekebalan lokal, peningkatan angiogenesis, dan diferensiasi sel induk dengan melibatkan faktor-faktor terlarut seperti IL-10, TGF-β1, IL-6, TNF-α dan faktor pertumbuhan endotel vaskular (VEGF). Aplikasi MSC-secretome pada kornea tikus setelah cedera secara in vivo diketahui mencegah perkembangan neovaskularisasi kornea. Mekanisme immunomodulasi MSC-secretome dalam memediasi regulasi inflamasi, angiogenesis dan neovaskularisasi pada gangguan permukaan okular dibahas dalam ulasan ini.

show abstract

“…Human umbilical cord stem cells also show potential in regeneration of eye tissues [ 151 ]. The effects of human umbilical cord stem cell-derived exosomes were investigated on subretinal fibrosis in vivo and in vitro [ 152 ]. Exosomes are nano-sized vesicles released from cells that deliver proteins, lipids, mRNA, and miRNA to neighboring or distant cells.…”

Section: Cell-based Therapiesmentioning

confidence: 99%

“…Stem cell-derived exosomes showed potential in treatment ocular tissue fibrosis by transferring their molecular contents [ 153 ]. Intravitreal injection of human umbilical cord-derived exosomes effectively reduced subretinal fibrosis in vivo [ 152 ]. Moreover, exosomes can be loaded with therapeutic miRNA.…”

Section: Cell-based Therapiesmentioning

confidence: 99%

Understanding Drivers of Ocular Fibrosis: Current and Future Therapeutic Perspectives

Mallone

Costi

Marenco

et al. 2021

IJMS

View full text Add to dashboard Cite

Ocular fibrosis leads to severe visual impairment and blindness worldwide, being a major area of unmet need in ophthalmology and medicine. To date, the only available treatments are antimetabolite drugs that have significant potentially blinding side effects, such as tissue damage and infection. There is thus an urgent need to identify novel targets to prevent/treat scarring and postsurgical fibrosis in the eye. In this review, the latest progress in biological mechanisms underlying ocular fibrosis are discussed. We also summarize the current knowledge on preclinical studies based on viral and non-viral gene therapy, as well as chemical inhibitors, for targeting TGFβ or downstream effectors in fibrotic disorders of the eye. Moreover, the role of angiogenetic and biomechanical factors in ocular fibrosis is discussed, focusing on related preclinical treatment approaches. Moreover, we describe available evidence on clinical studies investigating the use of therapies targeting TGFβ-dependent pathways, angiogenetic factors, and biomechanical factors, alone or in combination with other strategies, in ocular tissue fibrosis. Finally, the recent progress in cell-based therapies for treating fibrotic eye disorders is discussed. The increasing knowledge of these disorders in the eye and the promising results from testing of novel targeted therapies could offer viable perspectives for translation into clinical use.

show abstract

Human Umbilical Cord-Mesenchymal Stem Cells: A Promising Strategy for Corneal Epithelial Regeneration

Cited by 8 publications

References 43 publications

Mesenchymal Stromal Cell–Based Therapy for Dry Eye: Current Status and Future Perspectives

Mesenchymal Stromal Cell–Based Therapy for Dry Eye: Current Status and Future Perspectives

Sel Induk Mesenchymal Secretome untuk Gangguan Permukaan Okular

Understanding Drivers of Ocular Fibrosis: Current and Future Therapeutic Perspectives

Contact Info

Product

Resources

About